BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28133783)

  • 1. Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation.
    Jentzsch M; Bill M; Nicolet D; Leiblein S; Schubert K; Pless M; Bergmann U; Wildenberger K; Schuhmann L; Cross M; Pönisch W; Franke GN; Vucinic V; Lange T; Behre G; Mrózek K; Bloomfield CD; Niederwieser D; Schwind S
    Am J Hematol; 2017 Apr; 92(4):388-396. PubMed ID: 28133783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment CD34
    Jentzsch M; Geus U; Grimm J; Vucinic V; Pönisch W; Franke GN; Behre G; Niederwieser D; Schwind S
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1560-1566. PubMed ID: 30928626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
    Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
    van Rhenen A; Feller N; Kelder A; Westra AH; Rombouts E; Zweegman S; van der Pol MA; Waisfisz Q; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Sep; 11(18):6520-7. PubMed ID: 16166428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
    de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.
    Plesa A; Elhamri M; Clapisson G; Mattei E; Gazzo S; Hequet O; Tigaud I; Michallet M; Dumontet C; Thomas X
    Leuk Lymphoma; 2015 Mar; 56(3):622-9. PubMed ID: 24884314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
    Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M; Zeijlemaker W; Kelder A; Rutten AP; Snel AN; Scholten WJ; Pabst T; Verhoef G; Löwenberg B; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
    Gerber JM; Smith BD; Ngwang B; Zhang H; Vala MS; Morsberger L; Galkin S; Collector MI; Perkins B; Levis MJ; Griffin CA; Sharkis SJ; Borowitz MJ; Karp JE; Jones RJ
    Blood; 2012 Apr; 119(15):3571-7. PubMed ID: 22262762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
    Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
    Xie W; Wang X; Du W; Liu W; Qin X; Huang S
    Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
    Wang L; Gao L; Xu S; Gong S; Chen L; Lü S; Chen J; Qiu H; Xu X; Ni X; Song X; Zhang W; Yang J; Liu M; Hu X; Wang J
    J Hematol Oncol; 2013 Nov; 6(1):85. PubMed ID: 24517186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.
    Kong Y; Xu LP; Liu YR; Qin YZ; Sun YQ; Wang Y; Jiang H; Jiang Q; Chen H; Chang YJ; Huang XJ
    Bone Marrow Transplant; 2015 Mar; 50(3):348-53. PubMed ID: 25486581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.